Yan Shi

发表

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

Yan Shi, S. C. Panchal, Eric F. Johnson, 2015, Molecular Cancer Research.

Autophagy induction and antiproliferative effect of a novel curcumin derivative MOMI‐1 on the human lung cancer cells A549

Yan Shi, Guang-Zhou Zhou, Lin Wei, 2018, Journal of biochemical and molecular toxicology.

PARP inhibitors attenuate chemotherapy‐induced painful neuropathy

K. Browman, X. Liu, V. Giranda, 2012, Journal of the peripheral nervous system : JPNS.

Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

Eric F. Johnson, X. Liu, V. Giranda, 2009, Bioorganic & medicinal chemistry letters.

The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Anticancer research.

Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks

Eric F. Johnson, X. Liu, V. Giranda, 2008, Molecular Cancer Research.

Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors

P. Ellis, X. Liu, V. Giranda, 2009, Clinical Cancer Research.

An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.

P. Ellis, X. Liu, V. Giranda, 2008, Analytical biochemistry.

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

S. C. Panchal, Mikkel A. Algire, P. Ellis, 2018, Molecular Cancer Research.

Novel Peroxisome Proliferator-Activated Receptor α Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist

M. Blanar, Rongan Zhang, Jun Li, 2008, Journal of Pharmacology and Experimental Therapeutics.

Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist.

M. Blanar, Rongan Zhang, S. Krystek, 2016, ACS medicinal chemistry letters.

Inhibition of the α-mannosidase Man2c1 gene expression enhances adhesion of Jurkat cells

Shuang-ling Chen, Y. Zhou, Yan Shi, 2006, Cell Research.

CDK4-mediated MnSOD activation and mitochondrial homeostasis in radioadaptive protection.

A. Vaughan, G. Woloschak, Rulong Z. Shen, 2015, Free radical biology & medicine.

Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo.

J. Fisher, X. Liu, V. Giranda, 2005, Neoplasia.

Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors

C. Tse, K. Longenecker, P. Richardson, 2017, Molecular Cancer Therapeutics.

Ubiquitin-specific Cysteine Protease 2a (USP2a) Regulates the Stability of Aurora-A

Eric F. Johnson, X. Liu, V. Giranda, 2011, The Journal of Biological Chemistry.

Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.

Eric F. Johnson, X. Liu, V. Giranda, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.

Eric F. Johnson, X. Liu, V. Giranda, 2006, Bioorganic & medicinal chemistry.

Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.

Eric F. Johnson, X. Liu, V. Giranda, 2010, Journal of medicinal chemistry.

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

Eric F. Johnson, X. Liu, V. Giranda, 2009, Molecular Cancer Research.

ABT-888 , an OrallyActive Poly ( ADP-Ribose ) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in PreclinicalTumorModels

Eric F. Johnson, T. DeWeese, X. Liu, 2007 .

Synthesis and evaluation of acylguanidine FXa inhibitors.

E. Liu, P. Stein, Yan Shi, 2008, Bioorganic & medicinal chemistry letters.

Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.

P. Ellis, Eric F. Johnson, X. Liu, 2012, Bioorganic & medicinal chemistry.

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Eric F. Johnson, T. DeWeese, X. Liu, 2007, Clinical Cancer Research.

Aminopyrimidinone cdc7 kinase inhibitors.

Eric F. Johnson, N. Soni, J. Miyashiro, 2012, Bioorganic & medicinal chemistry letters.

Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Bioorganic & medicinal chemistry.

Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Bioorganic & medicinal chemistry letters.

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2009, Journal of medicinal chemistry.

Oxymatrine induces A549 human non‑small lung cancer cell apoptosis via extrinsic and intrinsic pathways.

Yan Shi, Guang-Zhou Zhou, A-Fang Li, 2017, Molecular medicine reports.

Synthesis and Fungicidal Activity of Lansiumamide A and B and Their Derivatives

M. Ouyang, Ting-Wei Chen, Yan Shi, 2018, Molecules.

Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.

Eric F. Johnson, X. Liu, V. Giranda, 2006, Bioorganic & medicinal chemistry letters.

Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression.

X. Liu, J. Wilsbacher, V. Giranda, 2008, Neoplasia.

Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis

X. Liu, V. Giranda, Yan Luo, 2006, Molecular Cancer Therapeutics.

Rationale for the combination of veliparib with platinum-based chemotherapy.

Eric F. Johnson, T. Penning, E. DiGiammarino, 2015 .

246 PARP inhibitors trap PARP1 onto damaged DNA via catalytic inhibition and not by an allosteric mechanism

Eric F. Johnson, E. DiGiammarino, L. Solomon, 2014 .

Abstract 2734: Veliparib (ABT-888) potentiates the cytotoxic activity of DNA alkylating agents by trapping PARP onto damaged chromatin

P. Ellis, Eric F. Johnson, G. Fang, 2014 .

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

John E. Harlan, Ramesh Iyer, Yan Shi, 2011, Clinical Cancer Research.

Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.

P. Ellis, Eric F. Johnson, N. Soni, 2009, Journal of medicinal chemistry.

Geniposidic Acid Confers Neuroprotective Effects in a Mouse Model of Alzheimer’s Disease through Activation of a PI3K/AKT/GAP43 Regulatory Axis

Q. Y. Chen, Yan Shi, W. He, 2021, The Journal of Prevention of Alzheimer's Disease.

Mechanistic Dissection of PARP 1 Trapping and the Impacton InVivo TolerabilityandEf fi cacyofPARP Inhibitors

Eric F. Johnson, J. Wilsbacher, E. DiGiammarino, 2015 .

Cancer Therapy : Preclinical Iniparib Nonselectively Modi fi es Cysteine-Containing Proteins in TumorCells and IsNot a Bona Fide PARP Inhibitor

P. Ellis, Eric F. Johnson, N. Soni, 2012 .

Development of a quantitative enzyme immunoassay for measurement of PAR as a pharmacodynamic biomarker of PARP activity

L. Rubinstein, J. Doroshow, X. Liu, 2006 .

[Differential gene expression in nasopharyngeal carcinoma cell with reduced and normal expression of 6A8 alpha-mannosidase].

Shuang-ling Chen, Yan Shi, Yin Liu, 2005, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

Quantitative Analysis of Anti-apoptotic Function of Akt in Akt1 and Akt2 Double Knock-out Mouse Embryonic Fibroblast Cells under Normal and Stressed Conditions*

M. Birnbaum, X. Liu, V. Giranda, 2006, Journal of Biological Chemistry.

[Experimental siCD44-targeted therapy of human nasopharyngeal carcinoma mediated by adenovirus].

Yan Shi, Lian Shen, Yin Liu, 2007, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

Downregulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cells.

X. Liu, V. Giranda, S. Ng, 2001, Neoplasia.

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2009, Journal of medicinal chemistry.